There are currently fraudulent e-mails and posts circulating, claiming to be from Combioxin. If you find the message suspicious, mark it as a phishing attempt. Legitimate email addresses from Combioxin ends with @combioxin.com (any other extension such as .co is not from Combioxin)

REVOLUTION IN THE TREATMENT OF SEVERE INFECTIONS

CAL02

Severe bacterial and viral infections

Combioxin is a Swiss-based biotechnology company dedicated to the development of first-in-class life-saving drugs for severe infections.

The company entered into worldwide licensing agreement with Eagle Pharmaceuticals for the commercial rights to its pipeline.

LATEST NEWS

Combioxin‘s licensee, Eagle Pharmaceuticals, announces acceptance of Investigational New Drug application to FDA for CAL02 for the treatment of severe community-acquired bacterial pneumonia

November 11, 2022

Combioxin announces worldwide licensing agreement with Eagle Pharmaceuticals for Phase 2b/3, first-in-class anti-virulence agent CAL02 for the treatment of severe pneumonia

August 25, 2021

Pneumonia is the most common infection requiring hospitalization and admission to the intensive care unit (ICU), and is the third most common cause of death globally with 2.4 million deaths per year

There are >300 million cases per year

2’400 / day

CHILDREN < 5 YEARS DYING
OF PNEUMONIA

2.4 million

DEATHS CAUSED ANNUALLY
BY PNEUMONIA

Up to 50%

MORTALITY RATES OF
SEVERE PNEUMONIA

MEET THE TEAM

Samareh Azeredo da Silveira

Managing Director

Frédéric Lajaunias

Managing Director

Toni Perez

Chief Medical Director

Shelly Bustion

Head of Clinical Ops

Kristen Peterson

Head of CMC

CONTACT US